Field Medical's Major $40 Million Funding Round
Field Medical Inc., a leader in cardiac pulsed field ablation (PFA) techniques, recently celebrated a significant milestone by completing a $40 million Series A financing round. This financing includes $20 million in fresh capital and the conversion of $20 million from seed-round debt, reflecting robust investor confidence in the company's mission to advance treatment methods for ventricular tachycardia (VT) and other cardiac arrhythmias.
Investors Backing Innovation
The financing was supported by a diverse group of strategic partners, venture capital firms, and family offices, who recognized Field Medical's potential. Notably, several early seed investors chose to reinvest, further showcasing trust in the company's innovative journey.
CEO Dr. Steven Mickelsen emphasized the importance of this achievement, stating, "This financing is a pivotal milestone as we advance in redefining how electrophysiologists approach ablation therapy." He continued, highlighting the impact of investor support in accelerating the FieldForce™ Ablation System's development, which aims to provide next-generation solutions for cardiac ablation.
Advancing Clinical Studies
The funds will primarily facilitate the completion of two critical pilot studies, VCAS for VT and Field PULSE for atrial fibrillation (AF). These studies are essential for demonstrating the system's capabilities and preparing for the upcoming VERITAS pivotal trial, which is focused on VT treatments.
Transformative Technology in Cardiac Care
Field Medical is committed to revolutionizing the treatment of all cardiac arrhythmias, including VT and AF. Their FieldForce Ablation System stands out with a unique, contact-force focal PFA catheter that dramatically enhances ablation workflows, allowing for rapid delivery of therapy. Recent pilot studies highlight its versatility, driven by FieldBending™, an innovative proprietary technology that generates brief yet powerful electric fields.
About Field Medical Inc.
Established in 2022, Field Medical has been at the forefront of developing cutting-edge pulsed field ablation technologies to meet the evolving demands of modern cardiac care. Dr. Steven Mickelsen, a trailblazer in pulsed electric field advances, leads the organization. His foundational efforts in PFA have paved the way for continual innovations within the field.
With recognition from the FDA as a Breakthrough Device and inclusion in the TAP Pilot Program, Field Medical is poised to influence the future of cardiac treatments significantly.
Growing Demand for Cardiac Treatments
Ventricular tachycardia and atrial fibrillation are among the most prevalent and severe cardiac arrhythmias, leading to serious health complications such as stroke and heart failure. VT and premature ventricular contractions affect over 6 million individuals in the U.S. and Europe, while AF impacts about 2% to 6% of people worldwide.
The catheter ablation market for AF is valued at approximately $5 billion and is expected to grow at a compound annual growth rate of 13% to 16%, potentially exceeding $11 billion by 2034. Conversely, the global VT market, incorporating devices and catheter procedures, was estimated at roughly $12.5 billion in 2021, with projections indicating it could reach $17 billion by 2027, particularly due to the rising adoption of catheter-based treatments.
Frequently Asked Questions
What is the amount raised in Field Medical's Series A financing?
Field Medical closed a total of $40 million in its Series A financing round.
What will the funding support for Field Medical?
The funding will support the completion of two pilot studies and further development of the FieldForce Ablation System.
Who is the CEO of Field Medical?
The CEO of Field Medical is Dr. Steven Mickelsen, who is a pioneer in pulsed electric field technology.
What distinguishes the FieldForce Ablation System?
The FieldForce Ablation System features a unique contact-force focal PFA catheter for rapid and efficient cardiac ablation.
What market trends are driving the growth of cardiac ablation technologies?
The increasing prevalence of ventricular tachycardia and atrial fibrillation is driving significant growth in the cardiac ablation market.
